Biotech Values

[DewDiligence]

HALO/BAX:

Current i.v. formulations are once/month. Baxter is working with HALO and in P3 for an injectable, one injection, once/month.

However, BAX’s own injectable IVIG will hit the market before BAX’s product based on HALO’s technology. From BAX’s 1Q10 CC:

http://seekingalpha.com/article/200235-baxter-international-inc-q1-2010-earnings-call-transcript?page=-1

We have a 30 gram IVIG product we hope to get approved this year and hopefully launch in the U.S. by the end of this year. We have a 10% sub-q product without Enhance—without the Hylenex technology—that we will be submitting shortly and hope to have on the market in 2011. Then of course HYQ which incorporates the Hylenex technology we are very excited about. Then new indications like MMN [multifocal motor neuropathy] and the whole Alzheimer’s thing which we don’t need to get into.